524804 Stock Overview
A biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 524804 from our risk checks.
Aurobindo Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,235.15 |
| 52 Week High | ₹1,592.55 |
| 52 Week Low | ₹959.05 |
| Beta | 0.59 |
| 11 Month Change | -16.11% |
| 3 Month Change | -19.44% |
| 1 Year Change | 23.74% |
| 33 Year Change | 96.77% |
| 5 Year Change | 180.43% |
| Change since IPO | 1,690.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524804 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -4.1% | -3.0% | -3.3% |
| 1Y | 23.7% | 42.9% | 27.5% |
Return vs Industry: 524804 underperformed the Indian Pharmaceuticals industry which returned 42.9% over the past year.
Return vs Market: 524804 underperformed the Indian Market which returned 27.5% over the past year.
Price Volatility
| 524804 volatility | |
|---|---|
| 524804 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 524804 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524804's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 26,015 | Kambam Reddy | www.aurobindo.com |
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams.
Aurobindo Pharma Limited Fundamentals Summary
| 524804 fundamental statistics | |
|---|---|
| Market cap | ₹717.52b |
| Earnings (TTM) | ₹35.82b |
| Revenue (TTM) | ₹302.95b |
20.0x
P/E Ratio2.4x
P/S RatioIs 524804 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524804 income statement (TTM) | |
|---|---|
| Revenue | ₹302.95b |
| Cost of Revenue | ₹128.77b |
| Gross Profit | ₹174.18b |
| Other Expenses | ₹138.36b |
| Earnings | ₹35.82b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 61.67 |
| Gross Margin | 57.49% |
| Net Profit Margin | 11.82% |
| Debt/Equity Ratio | 26.2% |
How did 524804 perform over the long term?
See historical performance and comparison